Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (OptIMize)

maanantai 9. marraskuuta 2026 päivittänyt: Geron Corporation

A Randomized, Single-Blind, Multicenter Phase 4 Trial Evaluating Two Imetelstat Doses in Participants With Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS)

This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.

The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.

Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.

Taking part is voluntary. Participants may leave the study at any time.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

100

Vaihe

  • Vaihe 4

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Man or woman greater than or equal to (≥) 18 years of age
  • Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and biopsy within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
  • RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion Hgb should be ≤ 9.0 g/dL to count towards the 4 units total.
  • Relapsed/refractory to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

Exclusion Criteria:

  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
  • Prior treatment with imetelstat
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days of randomization
  • Has received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
  • Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or immunosuppressive therapy, within 4 weeks prior to randomization

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Muut: Arm A: imetelstat 7.1 mg/kg

Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Kokeellinen: Arm B: imetelstat 3.55 mg/kg

Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study.

imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL
Aikaikkuna: Weeks 1-24

Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of Grade 3/4 thrombocytopenia by laboratory values
Aikaikkuna: Weeks 1-24

Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any

Weeks 1-24

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Rate of ≥ 12 weeks RBC TI
Aikaikkuna: Weeks 1-24

Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL
Aikaikkuna: Up to End of Study (approximately 3.5 years)

It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any.

Up to End of Study (approximately 3.5 years)
Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Duration of RBC TI Response
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started.

Up to End of Study (approximately 3.5 years)
Time to RBC TI Response
Aikaikkuna: Up to End of Study (approximately 3.5 years)

It is defined as the interval from randomization to the first day of corresponsive RBC TI response

Up to End of Study (approximately 3.5 years)
Hgb peak and rise
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level

Up to End of Study (approximately 3.5 years)
Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018
Aikaikkuna: Up to End of Study (approximately 3.5 years)

For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks.

For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry):

  • Major HI-E response per revised IWG 2018 is defined as 16-week RBC TI.
  • Minor HI-E response per revised IWG 2018 is defined as a reduction by at least 50% of RBC units over a 16-week period compared with the 16 weeks prior to trial entry.
Up to End of Study (approximately 3.5 years)
Rate of disease progression, including AML progression
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria

Up to End of Study (approximately 3.5 years)
Rate of Grade 3/4 neutropenia by laboratory values
Aikaikkuna: Weeks 1-24

Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any

Weeks 1-24
Treatment Emergent Adverse Events (TEAEs)
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test [LFT] abnormalities)

Up to End of Study (approximately 3.5 years)
Time to Resolution of Lab Events
Aikaikkuna: Up to End of Study (approximately 3.5 years)

Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing.

Up to End of Study (approximately 3.5 years)
Assessment of Plasma concentrations of imetelstat
Aikaikkuna: Cycles 1-6 (28 day cycles)

Concentrations of imetelstat in Plasma

Cycles 1-6 (28 day cycles)
Assessment of Cmax
Aikaikkuna: Cycles 1-6 (28 day cycles)

Maximum Observed Plasma Concentration (Cmax)

Cycles 1-6 (28 day cycles)
Assessment of AUC
Aikaikkuna: Cycles 1-6 (28 day cycles)

Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration

Cycles 1-6 (28 day cycles)
Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks
Aikaikkuna: Cycles 1-6 (28 day cycles)
Cycles 1-6 (28 day cycles)

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Time to acute myeloid leukemia (AML) progression among participants with documented AML progression
Aikaikkuna: Up to End of Study (approximately 3.5 years)
Up to End of Study (approximately 3.5 years)
Assessment of biomarkers
Aikaikkuna: Cycles 1-2 (28 day cycles)

At baseline and change from baseline

Cycles 1-2 (28 day cycles)
Assessment of Mutation status
Aikaikkuna: Up to End of Study (approximately 3.5 years)

At baseline and change from baseline including at the time of suspected progression

Up to End of Study (approximately 3.5 years)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Joseph E Eid, MD, Geron Corporation

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 1. maaliskuuta 2027

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. heinäkuuta 2030

Opintojen valmistuminen (Arvioitu)

Keskiviikko 1. tammikuuta 2031

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 3. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 16. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa